Alaunos Therapeutics, Inc. (TCRT)
| Market Cap | 4.82M +12.1% |
| Revenue (ttm) | 3,000 -72.7% |
| Net Income | -4.22M |
| EPS | -2.07 |
| Shares Out | 2.42M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 26,874 |
| Open | 2.060 |
| Previous Close | 2.000 |
| Day's Range | 1.960 - 2.060 |
| 52-Week Range | 1.670 - 6.200 |
| Beta | -1.06 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 15, 2026 |
About TCRT
Alaunos Therapeutics, Inc., a pre-clinical stage biopharmaceutical company that develops orally administered small-molecule therapeutics for the treatment of obesity and related metabolic disorders. It develops non-hormonal, non-incretin approach, and unlike hormone-based treatments, such as GLP-1 drugs. The company also develops hunTR TCR discovery platform to target driver mutations. Alaunos Therapeutics, Inc. was founded in 2003 and is based in Fort Lauderdale, Florida.
Financial Performance
In 2025, Alaunos Therapeutics's revenue was $5,000, a decrease of -50.00% compared to the previous year's $10,000. Losses were -$4.28 million, -8.48% less than in 2024.
Financial StatementsNews
Alaunos Therapeutics reports metabolic improvements with ALN1003 in studies
Alaunos Therapeutics (TCRT) reported an integrated preclinical readout for ALN1003, the company’s investigational oral, non-hormonal, non-incretin small-molecule candidate for obesity and related meta...
Alaunos Reports Broad Metabolic Improvements with ALN1003 in Obese Mouse Studies
ALN1003 demonstrated consistent, favorable effects across key drivers of metabolic disease, including reductions in body weight and fat mass, improved insulin sensitivity, enhanced adipose function, a...
Alaunos Therapeutics reports updated preclinical data from ALN1003 mouse studies
Alaunos Therapeutics (TCRT) announced updated preclinical data from non-GLP diet-induced obesity mouse studies evaluating ALN1003, the company’s investigational oral metabolic therapeutic candidate. A...
Alaunos Reports Preclinical ALN1003 Data Showing Effects on Insulin-Resistance-Related Biomarkers and Liver Histology in Diet-Induced Obesity Models
FORT LAUDERDALE, Fla., May 18, 2026 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (Nasdaq: TCRT) today announced updated preclinical data from non-GLP diet-induced obesity (DIO) mouse studies evaluat...
Alaunos Therapeutics Quarterly report: Q1 2026
Alaunos Therapeutics has published its Q1 2026 quarterly earnings report on May 15, 2026.
Valion Bio Appoints Melinda Lackey as General Counsel
Seasoned Biopharmaceutical Attorney with Deep IP, Clinical-Stage, and Nasdaq Public Company Experience Joins Leadership Team SAN ANTONIO, May 4, 2026 /PRNewswire/ -- Valion Bio, Inc. (formerly Tivic H...
Alaunos Therapeutics Annual report: Q4 2025
Alaunos Therapeutics has published its Q4 2025 annual report on March 31, 2026.
Alaunos Therapeutics reports ‘positive’ proof-of-concept data for ALN1003
Alaunos Therapeutics (TCRT) announced early data from two non-Good Laboratory Practice diet-induced obesity mouse studies evaluating ALN1003, the company’s lead small-molecule drug candidate for treat...
Alaunos Therapeutics Announces Positive Preclinical Proof-of-Concept Data for ALN1003, a Differentiated Non-Hormonal Oral Treatment for Obesity and Related Metabolic Disorders
Alaunos' ALN1003 shows dose dependent weight loss, better body composition, reduced liver weight, and improved liver biomarkers in preclinical studies.
Alaunos Therapeutics Quarterly report: Q3 2025
Alaunos Therapeutics has published its Q3 2025 quarterly earnings report on November 14, 2025.
Alaunos Therapeutics Registration statement: Registration Filing
Alaunos Therapeutics filed a registration statement on November 7, 2025, providing details about a securities offering with the SEC.
Alaunos Therapeutics Registration statement: Registration Filing
Alaunos Therapeutics filed a registration statement on October 22, 2025, providing details about a securities offering with the SEC.
Alaunos Therapeutics files to sell 327,740 shares of common for holders
06:35 EDT Alaunos Therapeutics (TCRT) files to sell 327,740 shares of common for holders
Alaunos Therapeutics Registration statement: Registration Filing
Alaunos Therapeutics filed a registration statement on October 2, 2025, providing details about a securities offering with the SEC.
Alaunos Therapeutics Registration statement: Registration Filing
Alaunos Therapeutics filed a registration statement on September 9, 2025, providing details about a securities offering with the SEC.
Alaunos Therapeutics Registration statement: Registration Filing
Alaunos Therapeutics filed a registration statement on August 21, 2025, providing details about a securities offering with the SEC.
Alaunos Therapeutics files $50M mixed securities shelf
06:07 EDT Alaunos Therapeutics (TCRT) files $50M mixed securities shelf
Alaunos Therapeutics Quarterly report: Q2 2025
Alaunos Therapeutics has published its Q2 2025 quarterly earnings report on August 14, 2025.
Alaunos prices 610,399 shares at $3.36 in registered direct offering
Alaunos Therapeutics (TCRT) entered into a definitive agreement with certain investors for the purchase and sale of an aggregate of 610,399 shares of common stock at a purchase price of…
Alaunos Therapeutics Announces $2.0 Million Registered Direct Offering
HOUSTON, June 23, 2025 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (Nasdaq: TCRT) (the “Company”) today announced that it has entered into a definitive agreement with certain investors (the “SPA”) ...
Alaunos Therapeutics Proxy statement: Proxy Filing
Alaunos Therapeutics filed a proxy statement on May 21, 2025, providing details for shareholder voting and corporate governance matters.
Alaunos Therapeutics Proxy statement: Proxy Filing
Alaunos Therapeutics filed a proxy statement on May 21, 2025, providing details for shareholder voting and corporate governance matters.
Alaunos Therapeutics Quarterly report: Q1 2025
Alaunos Therapeutics has published its Q1 2025 quarterly earnings report on May 15, 2025.
PMGC Capital announces filing to report 5.09% stake in Alaunos Therapeutics
PMGC Capital (ELAB) announced its planned filing of a Schedule 13D with the U.S. Securities and Exchange Commission disclosing beneficial ownership of common stock in Alaunos Therapeutics (TCRT). PMGC...
PMGC Capital LLC, a Subsidiary of PMGC Holdings Inc. (Nasdaq: ELAB), To File Schedule 13D Reporting 5.09% Stake in Alaunos Therapeutics, Inc. (Nasdaq: TCRT)
NEWPORT BEACH, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- PMGC Capital LLC (“PMGC Capital,” “we,” “our,” or “us”), a wholly owned subsidiary of PMGC Holdings Inc. (Nasdaq: ELAB), today announced its pla...